Novavax stock rises 1.45% on mixed trading day

9 articles · Updated · MarketWatch · May 1

Shares closed at $8.04 as the Nasdaq gained 0.89% to 25,114.44 and the Dow fell 0.31% to 49,499.27.
Novavax outperformed Johnson & Johnson and Pfizer, whose shares fell, but lagged Merck, which rose 2.73%.
The stock remains 32.83% below its 52-week high of $11.97 reached on 26 February, while trading volume of 3.1 million stayed below its 50-day average.

Novavax is finally profitable but forecasts lower revenue. Is this a successful pivot or a company managing its own decline?

As an activist investor cries 'value destruction,' can Novavax's new Pfizer deal prove its technology is the real prize?

With new data showing fewer side effects, can Novavax's vaccine win over hesitant patients from dominant mRNA rivals?